Introduction
B cell chronic lymphocytic leukaemia (B-CLL) is the most common leukaemia worldwide but its aetiology is unknown. 1, 2 This leukaemia is identified by the accumulation of immunologically immature non-proliferating cells, which co-express CD5 and CD23 as well as the pan B cell markers CD19, CD20 and CD40. 1, 3 The malignancy is characterized by the failure of cells to undergo apoptosis rather than excessive cellular proliferation, resulting in the gradual accumulation of leukaemic B cells. 3 Drug resistance presents a great obstacle to the treatment of B-CLL and complete remission of the disease is uncommon. However, recent work has demonstrated that proteasome inhibitors potently induce apoptosis in B-CLL cells in vitro. MG132 induced apoptosis in glucocorticoid-resistant B-CLL cells, 4 and lactacystin activated apoptotic cell death and sensitised resistant B-CLL cells to TNF␣-induced apoptosis. 5, 6 Caspases, a family of aspartate-specific cysteine proteases, are responsible for many of the characteristic biochemical and morphological changes associated with the execution phase of apoptosis. 7, 8 'Initiator' caspases with long prodomains such as caspases-8, -9 and -10 either directly or indirectly activate 'effector' caspases, such as caspases-3, -6 and -7, which have short prodomains. These effector caspases then cleave intracellular substrates such as poly (ADP-ribose) polymerase and lamins during the execution phase of apoptosis. 7, 8 Caspase-8 is the initiator caspase in death receptor-mediated apoptosis, such as CD95 (Fas/APO-1), whereas caspase-9 is the most upstream caspase in chemical-induced apoptosis. [9] [10] [11] [12] [13] Chemical-induced apoptosis results in perturbation of mitochondria followed by release of mitochondrial cytochrome c, which binds to Apaf-1. 11, 12, 14, 15 Apaf-1, the first mammalian CED-4 homologue, is an ෂ130 kDa protein which contains an Nterminal caspase recruitment domain (CARD) and a C-terminal domain containing WD40 repeats involved in proteinprotein interactions. 12 Following binding of cytochrome c, dATP/ATP binds to the CED-4 homology domain of Apaf-1 resulting in its oligomerisation. The CARD domain at the Nterminus of caspase-9 then binds to the CARD of Apaf-1 resulting in recruitment and activation of caspase-9, which subsequently activates the effector caspases-3 and -7, thereby initiating a caspase cascade that effectively dismantles the cell. This Apaf-1 containing complex has been referred to as the apoptosome. [16] [17] [18] Following dATP-dependent activation of lysates, we have previously described the formation of an ෂ700 kDa biologically active caspase processing complex and a larger ෂ1. 4 MDa biologically inactive apoptosome. 19 Additionally, we showed predominant formation of the ෂ700 kDa active complex in cells undergoing chemicalinduced apoptosis.
Caspase-2, -3, -7 and -8 are present in untreated B-CLL cells as their unprocessed zymogens and the effector caspases -3 and -7 are activated following the induction of apoptosis by the glucocorticoid, prednisolone or the alkylating agent chlorambucil, two agents commonly used in the treatment of CLL. [20] [21] [22] [23] Although caspases play a key role in the execution phase of apoptosis, much less is known about the role of the proteasome in apoptosis. The 26 S proteasome, the major extra-lysosomal machinery for protein degradation, is responsible for the ATP-dependent degradation of proteins targeted for destruction by ubiquitin. 24 These include short-lived regulatory proteins critical for cell proliferation and cell cycle regulation such as the tumor suppressor p53, various cyclins and the cyclin-dependent kinase inhibitor p27 Kip1 . 25 The proteasome is also important for the processing and degradation of NF-B and IB and for the proteolysis of other transcription factors including c-fos and c-jun. 26 Proteasomal activity appears essential for the survival of proliferating cells as treatment with proteasome inhibitors results in apoptosis, which is most probably due to the accumulation of short-lived regulatory proteins such as p53, p27
Kip1 and c-myc. [26] [27] [28] [29] [30] [31] In contrast treatment of quiescent or terminally differentiated cells, such as thymocytes or neuronal cells, blocks cell death induced by diverse agents 32, 33 suggesting that they may act by blocking the proteasome-mediated proteolysis of a caspase inhibitor. 25 Taken together these data support the hypothesis that the pro-teasome acts upstream of caspases and may be a therapeutic target in certain malignancies. A potential anti-cancer role for proteasome inhibitors has previously been described, showing that they can induce apoptosis in human prostate carcinoma cells independent of functional Bcl-2 and p53 34 and that they can inhibit tumour growth. 35, 36 Inhibition of NF-B activity by proteasome inhibitors has been proposed as a mechanism for induction of apoptosis in B-CLL cells, 4, 5 however, in a recent study no alterations of nuclear NF-B, or cytoplasmic IB␣, were observed after treatment with lactacystin. 6 In this study we investigated the execution mechanisms involved in proteasome inhibitor-induced apoptosis of B-CLL cells. We show proteasomal inhibitors induce apoptosis by formation of an ෂ700 kDa caspase-activating apoptosome complex containing Apaf-1, thus initiating a post-mitochondrial caspase cascade with caspase-9 as the initiator caspase.
Materials and methods

Materials
Lactacystin was from Affiniti Research Products (Exeter, UK) and MG132 (carbobenzoxyl-leucinyl-leucinyl-leucinal) from Calbiochem (La Jolla, CA, USA). LLnL (N-acetyl-n-leucinyl-lleucinyl-l-norleucinal, calpain inhibitor I), prednisolone, chlorambucil, propidium iodide and Hoechst 33342 were from Sigma (Poole, UK). Annexin V-FITC was from Bender MedSystems (Vienna, Austria) and DiOC 6 (3) (3,3′ dihexyloxacarbocyanine iodide) was from Molecular Probes (Eugene, OR, USA). Benzyloxycarbonyl-Val-Ala-Asp (OMe)fluoromethyl ketone (Z-VAD.fmk) and benzyloxycarbonyl-Asp-Glu-Val-Asp aminofluoromethyl coumarin (Z-DEVD.AFC) were from Enzyme Systems (Dublin, CA, USA).
B cell purification and culture
B-CLL patients, who had not received prior chemotherapy, were staged according to the Binet system. 37 Peripheral blood samples, obtained after informed consent and with local ethical committee approval, were purified as previously described 23 except that T cells were removed using anti-CD3 Dynabeads (Dynal, Merseyside, UK). B-CLL cell purity was assessed by staining with anti-CD19/FITC and anti-CD5/RPE antibodies (Dako, Cambridge, UK) and analysed by flow cytometry. This method produced an ෂ95% pure population of cells expressing both CD19 and CD5. Purified B-CLL cells were re-suspended in RPMI 1640 medium at a density of 1 to 4 × 10 
Quantification of apoptosis
Apoptotic cells were quantified by an increase in externalised phosphatidylserine as assessed by Annexin V binding. 23, 38 Apoptotic cells, with a reduced mitochondrial membrane potential (⌬⌿ m ), were assessed using DiOC 6 (3) (10 nm). 39 Apoptosis was also assessed using Hoechst 33342 40 with minor modifications. B-CLL cells (5 × 10 5 ) were suspended in 1 ml of medium, and incubated at 37°C for 1 min with Hoechst 33342 (1.5 g/ml), cooled on ice and re-suspended in cold PBS (700 l). Propidium iodide was added (5 g/ml), and the samples were analysed by flow cytometry. This method measures the increased cellular permeability of apoptotic cells 41 and corresponds very well with increases in Annexin V binding. 39 
Electron microscopy
Samples were prepared as described, 42 with modifications. B-CLL cells (6 × 10 6 ) were spun down at 400 g in a centrifuge with a swing-out rotor. The pellets were fixed overnight at 4°C, with 2% glutaraldehyde in 0.1 m sodium cacodylate buffer, pH 7.4. The samples were postfixed with 1% osmium tetroxide/1% potassium ferrocyanide, en bloc stained with 5% uranyl acetate, and embedded in Taab epoxy resin (Taab Laboratories, Aldermaston, UK).
Western blot analysis
Cell samples were prepared and proteins resolved on 10-15% SDS-polyacrylamide gels and blotted on to nitrocellulose membranes (Hybond C-extra; Amersham, Bucks, UK). 43 Caspases were detected as previously described. 13 The rabbit polyclonal antibody to caspase-2 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), recognises the intact proform and the p14 small subunit. 43 Apaf-1 was detected using a mouse monoclonal antibody to human Apaf-1 (R&D Systems, Minneapolis, MN, USA). Western blots were developed using enhanced chemiluminescence (ECL; Amersham) according to the manufacturer's instructions.
Fluorimetric assay of caspase activity
DEVDase activity (ie primarily caspases-3 and -7) of lysates or column fractions was measured ( ex / em = 405/510 nm) at 37°C in 96-well plates in 200 l of assay buffer (20 m Z-DEVD.AFC, 0.1% CHAPS, 10 mm DTT, 100 mm Hepes and 10% sucrose, pH 7.0) as described previously. 19 
Preparation of B-CLL lysates for in vitro activation studies
B-CLL cells were purified to the stage before negative selection as described above. These cells were Ͼ89% CD19 + and CD5 + . Cell lysates (10 mg/ml protein) were then prepared as described previously 43 and activated by addition of dATP (2 mm), cytochrome c (0.25 mg/ml) and MgCl 2 (1 mm).
Chromatographic methods
Lysates were fractionated by size-exclusion chromatography, using an FPLC protein purification system on a Superose 6 High Resolution 10/30 column (Amersham Pharmacia Biotech, Herts, UK) as described previously. 19 The Superose 6 column was eluted at 4°C, 0.4 ml/min, with 5% (w/v) sucrose, 0.1% (w/v) CHAPS, 20 mm Hepes/NaOH, 5 mm DTT, 50 mm NaCl, pH 7.0 and 0.5 ml fractions were collected. The columns were calibrated with protein standards (Amersham Pharmacia Biotech) as described. 19 
Assay of apoptosome effector caspase-activating activity
This assay measures the ability of an assembled Apaf-1 complex to both process and activate effector caspases-3 and -7. In preliminary experiments, fractionated active apoptosome complexes required neither dATP/ATP nor cytochrome c in order to process added procaspases, presumably because these cofactors are only required for the correct oligomerization of Apaf-1. Column fractions (100 l aliquots), from apoptosome complexes isolated from apoptotic or dATP-activated lysates by Superose-6 gel filtration as described above, were incubated with procaspases (25 g protein) for 30 min before assaying for DEVDase activity. The partially purified procaspases-3, -7 and -9 were obtained as described previously. 19 
Preparation of cytosolic extracts for cytochrome c analysis
Cell cytosols for assessment of cytochrome c release were prepared as previously described. 44 Briefly, cell pellets were resuspended in 2× volume lysate buffer supplemented with 250 mm sucrose, and incubated for 30 min at 4°C and then homogenised with a Dounce homogeniser (40 strokes). The cell extract was then centrifuged at 14 000 g for 15 min and the supernatant removed and stored at −80°C until assayed for cytochrome c by Western blotting. Cytochrome c was detected using a mouse monoclonal antibody (Pharmingen, San Diego, CA, USA).
Results
Spontaneous apoptosis in purified B-CLL cells
Purified B-CLL cells from patients (Table 1) were cultured either alone, with prednisolone or chlorambucil, or with proteasome inhibitors, and apoptosis assessed by externalisation of phosphatidylserine. 23, 38 B-CLL cells apparently fail to die by apoptosis in vivo, yet culture of purified cells for 18 h resulted in a wide range of spontaneous apoptosis (4.7- 
Proteasome inhibitors are potent inducers of apoptosis in B-CLL cells
Neither chlorambucil nor prednisolone consistently induced apoptosis in purified B-CLL cells over 18 h, although in patient No. 7 (Table 1 ) prednisolone induced marked apoptosis. Interestingly, this patient's B-CLL cells were resistant to chlorambucil in vivo but underwent a marked lymphocytolysis when treated with high doses of prednisolone. This suggested that in vitro sensitivity might be an indicator of in vivo sensitivity to chemotherapeutic agents in B-CLL patients. In contrast, lactacystin induced extensive apoptosis in cells from all patients studied (Table 1 and data not shown). Lactacystin is a specific, irreversible inhibitor of the proteasome, binding covalently to the amino-terminal threonine of the mammalian proteasome subunit X and not inhibiting the in vitro activity of any other known protease. 46 Lactacystin induced a time-and concentration-dependent induction of apoptosis in B-CLL cells, with almost complete apoptosis being observed after 24 h at higher concentrations (5-10 m) (Figure 1a) . B-CLL cells from all patients (n = 15) tested in this study have demonstrated a similar sensitivity to lactacystin. The cell permeable reversible proteasome inhibitors, MG132 and LLnL, 47 also induced apoptosis (Table 1 and Figure 1b ). MG132 caused a time-and concentration-dependent induction of apoptosis and was ෂ10-fold more potent than either LLnL or lactacystin. MG132 potently induced apoptosis in B-CLL cells purified from all patients (n = 10) tested in this study. Thus proteasome inhibitors induce apoptosis in B-CLL cells irrespective of the stage of the disease, or resistance to conventional chemotherapeutic agents.
Proteasome inhibitors induce an apoptotic morphology concomitant with loss in mitochondrial membrane potential and phosphatidylserine externalisation
Lactacystin and MG132 induced a time-dependent increase in the percentage of cells with decreased ⌬⌿ m , high Hoechst 33342 staining and phosphatidylserine exposure (Figure 2) . A reduction in ⌬⌿ m is an early event in the induction of apoptosis in many different systems. 48 Increased uptake of Hoechst 33342 has also been used to measure apoptosis in some systems. 40, 41 Thus proteasome inhibitor-induced apoptosis in B-CLL cells could be determined by three independent quantitative methods. Finally, both lactacystin and MG132 induced typical apoptotic ultrastructure in B-CLL cells (Figure 3) . In comparison to control cells (Figure 3a 6 ). Cytochrome oxidase, an inner mitochondrial membrane protein, was detected in the cell pellets containing the mito- chondria but not in the cytosolic extracts (data not shown) confirming that the mitochondria remained intact during the preparation of the extracts. The data suggested that the induction of apoptosis by proteasome inhibitors was preceded by a caspase-independent release of mitochondrial cytochrome c. The data agree with a previous study demonstrating that proteasomal inhibition resulted in mitochondrial cytochrome c release. 4 
Proteasome inhibitor-induced apoptosis is caspasedependent in B-CLL cells
Although pre-treatment with Z-VAD.fmk did not inhibit mitochondrial cytochrome c release, it completely abrogated MG132-induced apoptosis up to 8 h and largely inhibited it at 18 h (Figure 5a ). Treatment with MG132 caused a timedependent increase in DEVDase, a measure of the activity of effector caspases -3 and -7, which was completely abolished by Z-VAD.fmk (Figure 5b ). These data supported the involvement of effector caspases in the execution phase of MG132-induced apoptosis.
Activation of a caspase cascade in proteasome inhibitor treated B-CLL cells
B-CLL cells were examined for the processing of various initiator and effector caspases during the induction of apoptosis. Untreated cells contained the 46 kDa proform of caspase-9 (Figure 6a lane 1) , which on exposure to MG132 was processed to both an ෂ35 kDa fragment and smaller amounts of an ෂ37 kDa fragment (Figure 6a lanes 3-6) , resulting from cleavage between the large and small subunits at Asp 315 and Asp 330, respectively. 50 A time-dependent processing of caspase-9 was observed which was evident at 4 h, and almost complete at 18 h (Figure 6a lanes 2-6) . Treatment with Z-VAD.fmk did not completely inhibit the MG132 induced processing of caspase-9, although at 18 h some inhibition was evident as judged by more zymogen being present (Figure 6a lanes 7-11) . As caspase-9 processing was not completely inhibited by Z-VAD.fmk, we cannot totally exclude the possibility that mitochondrial cytochrome c release was caused by active caspase-9. However, this is unlikely as several studies have demonstrated that cytochrome c release pre- cedes activation of caspase-9 in a post mitochondrial caspaseactivation pathway. 11, 13 Caspase-3 is normally processed at Asp-175 between the large and small subunits yielding a p20 subunit, which is further processed at Asp-9 and Asp-28 to yield p19 and p17 large subunits. 51 Pro-caspase-3 was present in control B-CLL cells primarily as its inactive zymogen (Figure 6b lane 1) , which on exposure to MG132 was cleaved to form two fragments of ෂ19 kDa (p19) and ෂ17 kDa (p17) (Figure 6b ). Some processing was observed at 4 h and was complete at 18 h (Figure 6b lanes 3-6) . In the presence of Z-VAD.fmk, MG132 induced a time-dependent processing of pro-caspase-3 to the ෂ20 kDa (p20) fragment (Figure 6b lanes 7-11) , indicative of cleavage of pro-caspase-3 between the large and small sub-
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Figure 6
MG132 induces a time-dependent processing of caspases. B-CLL cells were incubated for up to 18 h either alone or in the presence of MG132 (1 m), with or without Z-VAD.fmk (200 m) as indicated. Cells were then analysed by immunoblotting for the processing of (a) caspase-9, (b) caspase-3, (c) caspase-7, (d) caspase-8 and (e) caspase-2 as described in Materials and methods. The proforms and processed forms of the caspases are indicated. A shorter exposure of the film showed that the proform of caspase-8 comprised two bands of ෂ55 and 53 kDa. The data are representative of three experiments using cells from different patients. Apoptosis was assessed by externalisation of phophatidylserine.
units by caspase-9, 50 which was not totally abrogated by the caspase inhibitor (Figure 6a lanes 7-11) . However, the accumulation of the p20 fragment, without further processing to the p19 and p17 fragments, demonstrated that Z-VAD.fmk blocked the autocatalytic activity of caspase-3.
51,52 Z-VAD.fmk also abolished MG132-induced DEVDase activity in B-CLL cells (Figure 5b ) demonstrating that the p20 fragment of caspase-3 was not catalytically active. Following exposure to MG132, a time-dependent loss of procaspase-7 was observed together with formation of an ෂ19 kDa (p19) fragment (Figure 6c) , which corresponds to the catalytically active large subunit.
51 Z-VAD.fmk blocked the processing of pro-caspase-7 to the p19 fragment (Figure 6c lanes 7-11) .
Caspase-8 was present in untreated B-CLL cells primarily as two isoforms of ෂ55 and 53 kDa (Figure 6d lane 1) , most probably corresponding to caspase-8a and -8b. 53 Following exposure to MG132, caspase-8 was also processed in a timedependent manner (Figure 6d ) to two fragments of ෂ43 and 41 kDa (p43 and p41, respectively), corresponding to cleavage of both caspase-8a and -8b between the large and small subunits. Caspase-8 was first processed at 4 h, and almost completely processed after 18 h (Figure 6d lanes 3-6) . Z-Leukemia VAD.fmk completely inhibited the time-dependent processing of caspase-8 induced by MG132 (Figure 6d lanes 7-11) .
Caspase-2 was present in B-CLL cells primarily as a 48 kDa proform (Figure 6e lane 1) , which on exposure to MG132, showed a time-dependent loss from 4 to 18 h (Figure 6e lanes  3-6) , which was largely inhibited by Z-VAD.fmk (Figure 6e  lanes 7-11) . The cells also contained an immunologically reactive protein of ෂ33 kDa (Figure 6e ), which we observed in an earlier study. 23 From the data it is not clear whether this represents a processed form of caspase-2. The processing of caspases-9, -3, -7, -8 and -2 in lactacystin-treated B-CLL cells had the same profile as that observed in MG132-treated cells (data not shown).
The data clearly demonstrated that the treatment of B-CLL cells with MG132 resulted in the initiation of a caspase cascade in which the processing of caspase -9 was independent of caspases -8, -2, -3 and -7. This strongly indicated that proteasome inhibitors induce apoptosis in B-CLL cells via a caspase cascade with caspase-9 as the initiator. Recently, we have shown that some chemical stimuli induce apoptosis by post-mitochondrial formation of a caspase-activating apoptosome complex. 16, 19 Therefore, we investigated whether a similar mechanism operated in B-CLL cells.
Formation of a functional apoptosome in B-CLL cell lysates
First, we used dATP-activated B-CLL lysates to determine whether they were capable of assembling a functional apoptosome. In control lysates, both procaspases -9 and -3 eluted as their free unprocessed zymogens and Apaf-1 eluted as a monomer (Figure 7a) . Following dATP activation, a marked change in the elution behaviour of Apaf-1 was observed, with it now being oligomerised and completely associated with ෂ1.4 MDa and ෂ700 kDa apoptosome complexes (Figure 7b , fractions 6-9 and fractions 10-16, respectively). After dATP activation, procaspase-9 was partially processed to its p35/p37 subunits, which eluted as free processed caspases (Figure 7b) , with very little of the processed fragments associated with the apoptosome complexes. Procaspase-3 was completely processed to its catalytically active large subunits (p17/19) (Figure 7b ), which co-eluted with all the DEVDase activity (Figure 7c , fractions 22-28, M r = ෂ60000). Most of the biological activity as assessed by ability to process effector caspases was associated with the ෂ700 kDa Apaf-1 containing apoptosome complex although a small amount of activity was also associated with the ෂ1.4 MDa apoptosome complex (Figure 7c ). Thus following dATP activation, lysates from B-CLL cells formed a fully functional, caspase activating ෂ700 kDa Apaf-1 containing apoptosome complex.
An ෂ700 kDa apoptosome complex is formed in apoptotic B-CLL cells
In order to determine whether a functional apoptosome was formed in apoptotic cells, B-CLL cells were treated with MG132. In control cells, Apaf-1 eluted as a monomer and procaspases-9 and -3 eluted as free caspases (Figure 8a ) as previously observed in lysates (Figure 7a) . Following exposure to MG132 (10 m) for 5 h, which resulted in ෂ40% apoptosis, processing of caspases-9 and -3 to their large subunits was observed (Figure 8b) . The processed caspase-3 corresponded to the DEVDase activity (compare Figure 8b and c, fractions An ෂ700 kDa apoptosome complex is formed following dATP activation of B-CLL cell lysates. Lysates (10 mg/ml protein) from B-CLL cells were incubated with or without dATP (2 mm), cytochrome c (0.25 mg/ml) and MgCl 2 (1 mm) for 1 h and the lysate (2.9 mg) separated on a Superose 6 column and immunoblotted. (a) Apaf-1 from control lysates eluted as a monomer and caspases-3 and -9 as their unprocessed zymogens. (b) After dATP activation, Apaf-1 eluted in two apoptosome complexes. Caspase-9 was partially processed to its p35 and 37 forms, which eluted as free heterotetramers. Caspase-3 was entirely processed to its active large subunit. (c) The ෂ700 kDa but not the ෂ1.4 MDa apoptosome possessed most of the ability to process and activate effector caspases. The Apaf-1-containing fractions (5-20, b) were assayed for caspase processing activity by measuring DEVDase activity (¼-¼) produced when the fractions were incubated with 'free caspases' as described in the Methods. Thus, the ෂ700 kDa apoptosome complex (fractions 10-16) initially had very little or no DEVDase activity but possessed the inherent ability to activate exogenous effector caspases. All the fractions from (b) were also initially assayed for DEVDase activity (᭺-᭺). The NaCl in the elution buffer resulted in the DEVDase (ie free active effector caspases-3 and -7) activity eluting in fractions 23-28. The positions of M r markers are indicated with arrows. The data are representative of three experiments using cell lysates from different patients. [22] [23] [24] [25] [26] . Some Apaf-1 clearly oligomerised to an ෂ700 kDa complex (Figure 8b, fractions 10-16 ), whilst most still eluted as free monomeric Apaf-1. The ෂ700 kDa Apaf-1 containing apoptosome complex possessed caspase processing activity (Figure 8c ).
With some patients it was more difficult to detect the formation of the apoptosome in response to treatment with MG132. The formation of a biologically active apoptosome was evident in activated lysates (Figure 7 ) produced from cells isolated from patient No. 27. Cells from this patient were also induced to undergo ෂ40% apoptosis by treatment with MG132 (1m) for 10 h, which resulted in processing of casp-
Figure 8
An ෂ700 kDa apoptosome complex is formed in apoptotic B-CLL cells. B-CLL cells were incubated for 5 h either alone (a), or (b) with MG132 (10 m) to induce ෂ40% apoptosis. Lysates were then prepared and fractionated by Superose 6 gel filtration. The fractions were run on SDS-PAGE and immunoblotted for Apaf-1, caspases-9 and -3, and assayed for effector caspase (DEVDase) and caspase processing activity. In control cells (a), Apaf-1 eluted as the monomeric form and there was no processing of caspases-9 and -3. In MG132-treated cells (b), Apaf-1 eluted both as its monomeric form and as an ෂ700 kDa apoptosome complex, and caspases-9 and -3 were processed/activated. Caspase processing activity was primarily associated with the ෂ700 kDa apoptosome complex (c). Control cell lysates did not have any detectable caspase processing activity (data not shown).
ases-3 and -9 to their p17/p19 and p35/p37 large subunits, respectively, which eluted as free caspases (Figure 9a , fractions 19-28). In this patient (No. 27), only a very small amount of oligomerised Apaf-1 eluted at ෂ700 kDa (Figure 9a , fractions 10-16) with a correspondingly small amount of caspase processing activity (Figure 9b, fractions 10-16) . Interestingly, the Apaf-1 antibody also detected an immunoreactive fragment of ෂ30 kDa (Figure 9a, fractions 25-29) , which was not present in the control cells (Figure 7a ) and corresponded to an ෂ30 kDa cleavage fragment of Apaf-1. 54 The data indicated that variable amounts of an Apaf-1 caspase activating apoptosome complex are formed in B-CLL cells induced to undergo apoptosis with proteasome inhibitors.
Discussion
Proteasome inhibitors potently induce apoptosis in B-CLL cells assessed by a number of criteria (Figures 1-5) . Although proteasome inhibitors have been reported to inhibit apoptosis in quiescent or differentiated cells, 32, 33 this clearly cannot be a general phenomenon as B-CLL is a disease characterised by quiescent malignant B lymphocytes largely arrested in the
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Figure 9
Minimal formation of an ෂ700 kDa apoptosome complex in some apoptotic B-CLL cells. B-CLL cells were incubated with MG132 (1 m) for 10 h to induce ෂ40% apoptosis. Lysates were prepared and fractions assayed as described in the legend to Figure 8 . In control cells from this patient (Figure 7a ), Apaf-1 eluted as a monomer and there was no processing of caspases-9 and -3. In MG132-treated cells (a), Apaf-1 eluted primarily as a monomer together with very small amounts of an ෂ700 kDa apoptosome complex. A cleaved ෂ30 kDa Apaf-1 fragment was also observed. Caspases-9 and -3 were processed to the catalytically active large subunits. There was very little caspase processing activity associated with the ෂ700 kDa apoptosome complex (b). Control cell lysates did not have any detectable caspase processing activity (Figure 7 ). G0/G1 phase of the cell cycle. [1] [2] [3] We describe for the first time the presence of five unprocessed caspases in control B-CLL cells all of which were processed/activated on induction of apoptosis. Our data support the hypothesis of a caspase cascade with caspase-9 as the initiator caspase. Some support for this hypothesis was provided by the observation that caspase-9 was still partially processed in the presence of Z-VAD.fmk ( Figure 6 ). Processed caspase-9 activates both caspases-3 and -7 following cleavage between their large and small subunits. These effector caspases then activate directly or indirectly caspases-8 and -2. This most probably occurs indirectly by caspase-6, as in dATP-activated lysates caspase-3 activates caspase-6, which in turn activates caspases-2 and -8. 55 Taken together, our data suggests that proteasome inhibitor-induced apoptosis of B-CLL cells proceeds via perturbation of mitochondria, resulting in cytochrome c release and initiation of a caspase cascade with caspase-9 as the initiator caspase.
Using both dATP-activated lysates and apoptotic B-CLL cells, we have demonstrated the formation of an ෂ700 kDa Apaf-1 containing caspase-activating complex (Figures 7-9 ) similar to that previously demonstrated in human monocytic THP.1 cells and in rat hepatoma cells. 19, 56 After dATP activation, we also observed formation of a larger ෂ1.4 MDa Apaf-1 apoptosome complex with reduced caspase processing activity. The lower activity of the larger complex appears to be due to inappropriate oligomerization of Apaf-1. 54 Interestingly, little if any processed or unprocessed caspase-9 was observed in either of the apoptosome complexes in lysates or cells (Figures 7-9 ). Caspase-9 binds tightly to Apaf-1 through Leukemia CARD-CARD interactions between the N-termini of caspase-9 and Apaf-1, 57, 58 suggesting that additional factors may be present in B-CLL cells that weaken the CARD-CARD interaction between caspase-9 and Apaf-1, resulting in dissociation of caspase-9 from apoptosome complexes during purification. Caspase-9 activity is dependent on it being bound to Apaf-1.
59,60 However, we have recently shown that processed caspase-9 can be recruited to the apoptosome complex and subsequently activate caspase-3. 61 Thus, the free processed caspase-9 present in cells and lysates from B-CLL cells could be similarly recruited to the apoptosome.
In B-CLL cells induced to undergo apoptosis by exposure to proteasome inhibitors, varying amounts of the biologically active ෂ700 kDa Apaf-1 containing complex were observed and the majority of the cellular Apaf-1 remained as its monomeric form (Figures 8 and 9 ), most probably because only 40% of the cells were apoptotic at the time-point examined.
In addition, amplification loops in caspase cascades may enable a modest level of apoptosome formation to initiate extensive caspase activation. Nevertheless, in cells from some patients induced to undergo similar levels of apoptosis, it was more difficult to detect formation of an active apoptosome ( Figure 9 ). In these experiments Apaf-1 was cleaved by caspase-3 to an ෂ30 kDa Apaf-1 immunoreactive fragment. 54 Although we had previously shown this fragment to associate with the ෂ1.4 MDa apoptosome complex, it was possible that the apoptosome may be rapidly degraded by active caspases in B-CLL cells making it difficult to detect. Alternatively, we cannot totally exclude the possibility that in cells from some patients, proteasome inhibitors activate caspases by an alternative mechanism not involving apoptosome formation.
In conclusion, our data indicated that proteasome inhibitors induce apoptosis in B-CLL cells via disruption of the mitochondria and release of cytochrome c, resulting in the formation of an Apaf-1 containing ෂ700 kDa caspase-activating complex that activates the initiator caspase-9. In B-CLL cells from some patients this large caspase-activating complex may be rapidly degraded by active caspases.
